Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Arrakis Therapeutics on the deal. Arrakis Therapeutics announced its research collaboration agreement with Amgen (NASDAQ:AMGN), focused on the discovery and development of RNA degrader...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vedere Bio II, Inc. on the deal. Vedere Bio II, Inc. announced its $77 million Series A financing. Vedere is developing next generation...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vedere Bio II, Inc. on the deal. Vedere Bio II, Inc. announced its $77 million Series A financing. Vedere is developing next generation...
You must be a Standard 1 Year member to access this content.
